Your browser doesn't support javascript.
loading
Comparison of growth dynamics in different types of MPS: an attempt to explain the causes.
Rózdzynska-Swiatkowska, Agnieszka; Zielinska, Anna; Tylki-Szymanska, Anna.
Affiliation
  • Rózdzynska-Swiatkowska A; Anthropology Laboratory, Children's Memorial Health Institute, Warsaw, Poland. agnieszka.rozdzynska@gmail.com.
  • Zielinska A; Anthropology Laboratory, Children's Memorial Health Institute, Warsaw, Poland.
  • Tylki-Szymanska A; Department of Paediatrics, Nutrition and Metabolic Diseases, Children's Memorial Health Institute, Warsaw, Poland.
Orphanet J Rare Dis ; 17(1): 339, 2022 09 05.
Article in En | MEDLINE | ID: mdl-36064607
ABSTRACT

BACKGROUND:

Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficient activity of enzymes responsible for the catabolism of glycosaminoglycans (GAGs), resulting in progressive damage to various tissues and organs. Affected individuals present with skeletal deformities, bone growth impairment, joint stiffness and frequently mental retardation.

RESULTS:

The objective of the study was to summarise over 30 years of observations of the growth dynamics in patients with different types of MPS, performed at the Children's Memorial Health Institute (CMHI, Warsaw, Poland). A retrospective analysis of anthropometric data collected from 1989 to 2020 was performed for 195 patients with MPS I, MPS II, MPS III, MPS IVA and MPS VI. Mean values for birth body length were statistically significantly greater than in the general population. The mean z-scores for other MPS groups showed that until the 24th month of life, the growth pattern for all patients was similar, and the average z-scores for body height were greater than in reference charts. Afterwards, growth patterns began to differentiate for MPS groups.

CONCLUSIONS:

The long-term follow up showed that the growth pattern in patients with all types of mucopolysaccharidoses significantly deviates from the general population. Patients with MPS IVA had the most severe growth impairments compared to other patients in the study group. Neuropathic MPS I and II demonstrated severe growth impairments compared to other patients in this study. Patients with MPS III showed the mildest growth impairments compared to other MPS patients and reached the 3rd percentile last.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis I / Mucopolysaccharidoses / Mucopolysaccharidosis III / Mucopolysaccharidosis IV / Mucopolysaccharidosis VI Type of study: Etiology_studies / Observational_studies Limits: Child / Humans Language: En Journal: Orphanet J Rare Dis Journal subject: MEDICINA Year: 2022 Document type: Article Affiliation country: Polonia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis I / Mucopolysaccharidoses / Mucopolysaccharidosis III / Mucopolysaccharidosis IV / Mucopolysaccharidosis VI Type of study: Etiology_studies / Observational_studies Limits: Child / Humans Language: En Journal: Orphanet J Rare Dis Journal subject: MEDICINA Year: 2022 Document type: Article Affiliation country: Polonia
...